Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cataract & MIGS cases in New York: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 7% on average (255 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 662 | 94,575 | 46% |
| 2020 | 575 | 72,810 | 48% |
| 2021 | 601 | 77,527 | 51% |
| 2022 | 603 | 87,790 | 53% |
| 2023 | 598 | 91,114 | 55% |
| 2024 | 588 | 82,565 | 57% |
| 2025 from claims | – | 82,733 75,926–87,532 | 58% |
| 2026 forecast | – | 83,663 73,610–96,543 | 58% |
| 2027 forecast | – | 84,245 72,020–100,394 | 59% |
| 2028 forecast | – | 84,817 70,772–103,856 | 59% |
| 2029 forecast | – | 85,379 69,735–107,073 | 60% |
| 2030 forecast | – | 85,929 68,841–110,117 | 60% |
Cataract extraction with IOL, with and without glaucoma stents; the ASC volume engine. Professional codes (what the surgeon bills): CPT 66984, 66982, 66989, 66991, 66987, 66988, 65820, 66174, 66183, 0671T, 0449T.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 9% of the cases CMS names in New York; 274 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 0% inpatient hospital, 25% hospital outpatient, 70% surgery center, 5% office. The share outside the hospital has moved +9 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 390 | 72,726−1.7%/yr | −1.7%/yr | 52.4 | 80% | 74,300 in 2030+0.4%/yr |
| Massachusetts | 256 | 48,337+1.2%/yr | +1.2%/yr | 50.4 | 83% | 55,500 in 2030+2.3%/yr |
| New Jersey | 259 | 44,451−1.6%/yr | −1.6%/yr | 41.8 | 95% | 46,300 in 2030+0.7%/yr |
| Connecticut | 117 | 25,053−0.3%/yr | −0.3%/yr | 74.2 | 80% | 30,200 in 2030+3.2%/yr |
| New Hampshire | 45 | 10,8700%/yr | 0%/yr | 47.3 | 79% | 12,900 in 2030+2.8%/yr |
| Rhode Island | 27 | 7,5280%/yr | 0%/yr | 80.9 | 89% | 11,900 in 2030+7.9%/yr |
| Maine | 24 | 5,023−10%/yr | −10%/yr | 31.2 | 86% | 4,850 in 2030−0.6%/yr |
| Vermont | 17 | 4,085−6.1%/yr | −6.1%/yr | 35.4 | 63% | 6,680 in 2030+8.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Vitreoretinal surgery | 42 | 3,504−3.3%/yr | −3.3%/yr | 1.91.0× | 48% | 3,660 in 2030+0.7%/yr |
Cataract & MIGS in every state, and its device makers · Every procedure market in New York · Every state · Compare with Pennsylvania
Alcon leads with 62% of company spending on these surgeons in 2025, +12 pts on 2024.
In 2025, 19 companies reported engagement with New York’s surgeons worth $919K in consulting, speaking, meals and travel tied to these products, about $1,562 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 46 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.